Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 354 Enz. Inhib. hit(s) with all data for entry = 10914
LigandPNGBDBM577720((rac)-4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-flu...)
Affinity DataIC50:  1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572202((rac)-4-chloro-12,12-difluoro-2,3-dimethyl-7-{3-[(...)
Affinity DataIC50:  1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572161((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50:  1nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577725((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577686(US11478451, Example 090 | US11478451, Example 091 ...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572210((9aS,11 aR)-3-chloro-4,5-dimethyl-15-{3-[(naphthal...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577711((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572202((rac)-4-chloro-12,12-difluoro-2,3-dimethyl-7-{3-[(...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572158((rac)-4-chloro-2,3,14-trimethyl-7-[3-(naphthalen-1...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577664((rac)-4-chloro-11,11-difluoro-2,3-dimethyl-7-[3-(1...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577704((rac)-4′-chloro-3′-ethyl-7′-{3-[...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577720((rac)-4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-flu...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577718((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577624((rac)-4-chloro-2,3-dimethyl-7-[3-(naphthalen-1-ylo...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577707((rac)-12-chloro-11-ethyl-1-{3-[(6-fluoronaphthalen...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572152((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572166((rac)-4-chloro-3-ethyl-2-methyl-7-[3-(naphthalen-1...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572192((rac)-4-chloro-3-ethyl-14-methyl-1-[2-(morpholin-4...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572175((rac)-12-chloro-10,11-dimethyl-1-[3-(naphthalen-1-...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572210((9aS,11 aR)-3-chloro-4,5-dimethyl-15-{3-[(naphthal...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572186((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572203(4-chloro-12,12-difluoro-2,3-dimethyl-7-{3-[(naphth...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577699((+)-3-chloro-4-ethyl-14-{3-[(6-fluoronaphthalen-1-...)
Affinity DataIC50:  1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572189((rac)-(11Z)-4-chloro-3-ethyl-14-methyl-1-[2-(morph...)
Affinity DataIC50:  1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577719((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)...)
Affinity DataIC50:  1.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577664((rac)-4-chloro-11,11-difluoro-2,3-dimethyl-7-[3-(1...)
Affinity DataIC50:  1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572208((rac) 4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577659((rac)-4-chloro-14-(2,2-difluoroethyl)-3-ethyl-7-{3...)
Affinity DataIC50:  1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572176((rac)-12-chloro-7,10,11-trimethyl-1-[3-(naphthalen...)
Affinity DataIC50:  1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572169((rac)-4-chloro-3-ethyl-2,14-dimethyl-7-[3-(naphtha...)
Affinity DataIC50:  1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572210((9aS,11 aR)-3-chloro-4,5-dimethyl-15-{3-[(naphthal...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577727((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572149(US11447504, Example 2 | US11447504, Example 3 | US...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572212((9aS,10aR or 9aR, 10aS)-3-chloro-4,5-dimethyl-14-{...)
Affinity DataIC50:  1.60nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572180((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572195((rac)-4-chloro-3-methyl-2-[3-(4-methylpiperazin-1-...)
Affinity DataIC50:  1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577659((rac)-4-chloro-14-(2,2-difluoroethyl)-3-ethyl-7-{3...)
Affinity DataIC50:  1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577728((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577668(US11478451, Example 072 | US11478451, Example 073 ...)
Affinity DataIC50:  1.80nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577731((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  2nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577716((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)...)
Affinity DataIC50:  2.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572205((rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]...)
Affinity DataIC50:  2.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577713((rac)-4-chloro-12-(2,2-difluoroethyl)-3-ethyl-7-{3...)
Affinity DataIC50:  2.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572210((9aS,11 aR)-3-chloro-4,5-dimethyl-15-{3-[(naphthal...)
Affinity DataIC50:  2.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577724((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50:  2.40nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM572212((9aS,10aR or 9aR, 10aS)-3-chloro-4,5-dimethyl-14-{...)
Affinity DataIC50:  2.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577723((rac)-4-chloro-3-ethyl-11,11-difluoro-7-{3-[(6-flu...)
Affinity DataIC50:  3.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577715((rac)-12-(4-acetoxybutyl)-4-chloro-3-ethyl-7-{3-[(...)
Affinity DataIC50:  3.10nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

Displayed 1 to 50 (of 354 total ) | Next | Last >>
Jump to: